 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Celltrion announced on the 17th that its autoimmune disease treatment, Remsima® SC, surpassed a 20% market share in Europe as of the first quarter. Citing pharmaceutical market research firm IQVIA, Celltrion reported this milestone, marking the first time since its launch in Europe in 2020 that it has achieved over 20% market share.
Remsima® SC is a subcutaneous injection formulation of Remsima, a biosimilar developed by Celltrion containing the active ingredient infliximab for autoimmune disease treatment. Celltrion attributed this success to tailored sales strategies implemented through its local subsidiaries across European countries, catering to specific national market characteristics.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
